Delivery Order SPE2DB22D9304-SPE2DB24FSSQ7

Award Date 4/2/24
Potential Completion Date 4/23/24
Potential Value $2.1K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, for the delivery of NEXPLANON 68 MG IMPLANTS. The contract, valued at $8,576.28, has an ultimate completion date of July 12, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group Inc., valued at up to $499,999,999, that allows the DLA to issue firm fixed-price delivery orders for a...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the procurement of NEXPLANON 68 MG IMPLANTS. The contract has a ceiling value of $4,288.14 and a period of performance through March 7, 2024. This delivery order contract is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract (IDC) with the DLA valued at $499,999,999, which enables the...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide 4,565,711,445 units of NEXPLANON 68 MG IMPLANTS. The delivery order, valued at $35,734.50, was issued under DMS Pharmaceutical Group's existing indefinite delivery contract (IDC) with the DLA, which has a ceiling value of up to $499,999,999 and runs through December 31, 2025. DMS Pharmaceutical Group is a key supplier in the federal...
The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide NEXPLANON 68 MG IMPLANTS. The contract has a ceiling value of $3,689.76 and an ultimate completion date of October 17, 2022. This delivery order is part of a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group Inc., valued at up to $499,999,999, which runs through December 31, 2025. The IDC allows the DLA to...
The U.S. Defense Logistics Agency (DLA) Troop Support Medical has awarded a firm fixed-price delivery order worth $3,573.45 to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of NEXPLANON 68 MG IMPLANTS. This order is placed under DMS Pharmaceutical Group's existing indefinite delivery contract 4600082013 with the DLA, valued up to $4,999,999 through 2025, which enables the agency to order a broad range of pharmaceutical products to support military health...
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order worth $2,777.24 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the procurement of NEXPLANON 68 MG IMPLANTS. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program. The IDC covers a wide range of pharmaceutical products, including branded and generic...
The U.S. Defense Logistics Agency Troop Support Medical has awarded a firm fixed price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide NEXPLANON 68 MG IMPLANTS. The total potential value of this order is $4,102.44, with a completion date of January 12, 2024. DMS Pharmaceutical Group Inc. is a leading pharmaceutical wholesaler that holds various federal contracts and indefinite delivery vehicles to supply pharmaceuticals and medical products to the...
The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide Nexplanon 68 mg implants. The contract, valued at $2,858.76, has an ultimate completion date of August 1, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group, valued at up to $499,999,999, which runs through December 31, 2025. The IDC allows the DLA to issue firm-fixed-price...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth up to $4,288.14 to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract is for the delivery of 4,564,134,203 units of the NEXPLANON 68 MG IMPLANTS contraceptive product. This order was placed against DMS Pharmaceutical Group's existing indefinite delivery contract SPE2DB with the DLA, valued at up to $4,999,999 through 2025. The DLA utilizes this vehicle to issue delivery...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the supply of NEXPLANON 68 MG IMPLANTS. The contract has a ceiling value of $29,587.68 and an ultimate completion date of October 3, 2022. This delivery order is part of a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group valued at up to $499,999,999, which runs through December 31, 2025. The...
  • SPE2DB22D9304
    Indefinite Delivery Contract
  • SPE2DB22D9304-SPE2DB24FSSQ7
    Delivery Order

The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order to DMS Pharmaceutical Group Inc. (DMS), a woman-owned small business, for the supply of NEXPLANON 68 MG IMPLANTS. The order has a ceiling value of $2,144.07 and an ultimate completion date of April 23, 2024. This Delivery Order is placed against DMS's Indefinite Delivery Vehicle (IDV) contract SPE2DB24FSSQ7 with DLA, which has a ceiling value of up to $4,999,999 and supports the recurring pharmaceutical needs of military health facilities worldwide. The IDV contract is not set-aside, but DMS's woman-owned small business status has enabled direct federal contract awards for pharmaceutical Prime Vendor programs supporting the Department of Defense and Department of Veterans Affairs.

Generated 7/2/24, 2:42 PM